Tenascin-C protects cancer stem-like cells from immune surveillance by arresting T-cell activation

Cancer Research

Volumn 75, Issue 10, 2015, Pages 2095-2108

  Jachetti, Elena ^a   Caputo, Sara ^a,b   Mazzoleni, Stefania ^a   Brambillasca, Chiara Svetlana ^a   Parigi, Sara Martina ^a   Grioni, Matteo ^a   Piras, Ignazio Stefano ^c   Restuccia, Umberto ^a   Calcinotto, Arianna ^a   Freschi, Massimo ^a   Bachi, Angela ^a   Galli, Rossella ^a   Bellone, Matteo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c Division of Regenerative Medicine Neural Stem Cell Unit IRCCS San Raffaele Scientific Institute ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CHEMOKINE RECEPTOR CXCR4; STROMAL CELL DERIVED FACTOR 1; T LYMPHOCYTE RECEPTOR; TENASCIN; VERY LATE ACTIVATION ANTIGEN 5;

ANIMAL CELL; ARTICLE; CANCER STEM CELL; CELL MIGRATION; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOSKELETON; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN FUNCTION; STRESS FIBER; T LYMPHOCYTE ACTIVATION; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; 129 MOUSE; ANIMAL; C57BL MOUSE; CELL MOTION; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPH NODE METASTASIS; LYMPHOCYTE ACTIVATION; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; T LYMPHOCYTE; TUMOR CELL CULTURE;

ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; INTEGRIN ALPHA5BETA1; LYMPHATIC METASTASIS; LYMPHOCYTE ACTIVATION; MALE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS; STRESS FIBERS; T-LYMPHOCYTES; TENASCIN; TUMOR CELLS, CULTURED; TUMOR ESCAPE;

EID: 84937965778     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-2346     Document Type: Article

References (50)

1. Klein CA. Parallel progression of primary tumours and metastases. Nat Rev Cancer 2009; 9: 302-12.
2. Husemann Y, Geigl JB, Schubert F, Musiani P., Meyer M, Burghart E, et al Systemic spread is an early step in breast cancer. Cancer Cell 2008; 13: 58-68.
3. Visvader JE, Lindeman GJ Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8: 755-68.
4. Hermann PC, Huber SL, Herrler T, Aicher A., Ellwart JW, Guba M, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1: 313-23.
5. Rhim AD, Mirek ET, Aiello N.M., Maitra A., Bailey JM, McAllister F, et al. EMT and dissemination precede pancreatic tumor formation. Cell 2012; 148: 349-61.
6. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007; 7: 834-46.
7. + cytolytic T cells. Cancer Res 2009; 69: 8886-93.
8. Castriconi R, Daga A, Dondero A., Zona G, Poliani PL, Melotti A, et al NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J Immunol 2009; 182: 3530-9.
9. Wei J, Barr J, Kong L.Y., Wang Y., Wu A, Sharma AK, et al Glioma-associated cancer-initiating cells induce immunosuppression. Clin Cancer Res 2010; 16:461-73.
10. Greenberg NM, De Mayo F, Finegold MJ, Medina D, Tilley W.D., Aspinall JO, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 1995; 92: 3439-43.
11. Shappell SB, Thomas GV, Roberts R.L., Herbert R., Ittmann MM, Rubin MA, et al. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 2004; 64: 2270-305.
12. Mazzoleni S, Jachetti E, Morosini S., Grioni M, Piras IS, Pala M, et al Gene signatures distinguish stage-specific prostate cancer stem cells from transgenic adenocarcinoma of the mouse prostate (TRAMP) lesions and predict the malignancy of human tumors. Stem Cells Trans Med 2013; 2: 678-89.
13. Jachetti E, Mazzoleni S, Grioni M., Ricupito A, Brambillasca C, Generoso L., et al. Prostate cancer stem cells are targets of both innate and adaptive immunity and elicit tumor-specific immune responses. Oncoimmunology 2013; 2: e24520.
14. Degl'Innocenti E, Grioni M, Boni A, Camporeale A, Bertilaccio MT, Freschi M, et al. Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. Eur J Immunol 2005; 35: 66-75.
15. Orend G, Chiquet-Ehrismann R. Tenascin-C induced signaling in cancer. Cancer Lett 2006; 244: 143-63.
16. Mombaerts P, Iacomini J, Johnson R.S., Herrup K., Tonegawa S, Papaioannou VE. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 1992; 68: 869-77.
17. Bellone M, Cantarella D, Castiglioni P., Crosti MC, Ronchetti A, Moro M, et al Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma. J Immunol 2000; 165: 2651-6.
18. Curnis F, Sacchi A, Longhi R., Colombo B, Gasparri A, Corti A. IsoDGR-tagged albumin: a new alphavbeta3 selective carrier for nanodrug delivery to tumors. Small 2013; 9: 673-8.
19. Restuccia U, Boschetti E, Fasoli E., Fortis F, Guerrier L, Bachi A., et al. pI-based fractionation of serum proteomes versus anion exchange after enhancement of low-abundance proteins by means of peptide libraries. J Proteomics 2009; 72: 1061-70.
20. Olsen JV, de Godoy LM, Li G, Macek B, Mortensen P., Pesch R, et al. Parts per million mass accuracy on an Orbitrap mass spectrometer via lock mass injection into a C-trap. Mol Cell Proteomics 2005; 4: 2010-21.
21. + T helper 1 cell differentiation. Immunity 2012; 37: 1091-103.
22. Hogquist KA, Jameson SC, Heath W.R., Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. Cell 1994; 76:17-27.
23. Barnden MJ, Allison J, Heath W.R., Carbone FR. Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunol Cell Biol 1998; 76: 34-40.
24. Schwartz RH. T cell anergy. Annu Rev Immunol 2003; 21: 305-34.
25. MacIver NJ, Michalek RD, Rathmell JC Metabolic regulation of T lymphocytes. Annu Rev Immunol 2013; 31: 259-83.
26. Oskarsson T, Acharyya S, Zhang X.H., Vanharanta S., Tavazoie SF, Morris PG, et al. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med 2011; 17: 867-74.
27. Ruegg CR, Chiquet-Ehrismann R, Alkan SS. Tenascin, an extracellular matrix protein, exerts immunomodulatory activities. Proc Natl Acad Sci U S A 1989; 86: 7437-41.
28. Nobes CD, Hall A. Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamel-lipodia, and filopodia. Cell 1995; 81: 53-62.
29. Woodside DG, Wooten DK, McIntyre BW Adenosine diphosphate (ADP)-ribosylation of the guanosine triphosphatase (GTPase) rho in resting peripheral blood human T lymphocytes results in pseudopodial extension and the inhibition of T cell activation. J Exp Med 1998; 188: 1211-21.
30. Wenk MB, Midwood KS, Schwarzbauer JE Tenascin-C suppresses Rho activation. J Cell Biol 2000; 150: 913-20.
31. Rougerie P, Delon J. Rho GTPases: masters of T lymphocyte migration and activation. Immunol Lett 2012; 142: 1-13.
32. Tybulewicz VL, Henderson RB Rho family GTPases and their regulators in lymphocytes. Nat Rev Immunol 2009; 9: 630-44.
33. Feller SM. Crk family adaptors-signalling complex formation and biological roles. Oncogene 2001; 20: 6348-71.
34. Rich S, Van Nood N, Lee HM. Role of alpha 5 beta 1 integrin in TGF-beta 1-costimulated CD8+ T cell growth and apoptosis. J Immunol 1996; 157: 2916-23.
35. Portella L, Vitale R, De Luca S, D'Alterio C, Ierano C, Napolitano M, et al. Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases. PLoS ONE 2013; 8: e74548.
36. Jiao J, Hindoyan A, Wang S., Tran LM, Goldstein AS, Lawson D, et al Identification of CD166 as a surface marker for enriching prostate stem/progenitor and cancer initiating cells. PLoS ONE 2012; 7: e42564.
37. Hubert RS, Vivanco I, Chen E., Rastegar S, Leong K, Mitchell S.C., et al. STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci U S A 1999; 96: 14523-8.
38. Reiter RE, Gu Z, Watabe T., Thomas G, Szigeti K, Davis E., et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A 1998; 95: 1735-40.
39. Pagliarulo V, Hawes D, Brands F.H., Groshen S., Cai J, Stein JP, et al Detection of occult lymph node metastases in locally advanced node-negative prostate cancer. J Clin Oncol 2006; 24: 2735-42.
40. Slater MD, Lauer C, Gidley-Baird A, Barden JA. Markers for the development of early prostate cancer. J Pathol 2003; 199: 368-77.
41. Fukunaga-Kalabis M., Martinez G, Nguyen T.K., Kim D., Santiago-Walker A, Roesch A, et al Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population. Oncogene 2010; 29: 6115-24.
42. Rizzieri DA, Akabani G, Zalutsky M.R., Coleman RE, Metzler SD, Bowsher JE, et al Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma. Blood 2004; 104: 642-8.
43. Hauzenberger D, Olivier P, Gundersen D., Ruegg C. Tenascin-C inhibits beta1 integrin-dependent T lymphocyte adhesion to fibronectin through the binding of its fnIII 1-5 repeats to fibronectin. Eur J Immunol 1999; 29:1435-47.
44. Puente Navazo M.D., Valmori D, Ruegg C. The alternatively spliced domain TnFnIII A1A2 of the extracellular matrix protein tenascin-C suppresses activation-induced T lymphocyte proliferation and cytokine production. J Immunol 2001; 167: 6431-40.
45. Mescher MF, Popescu FE, Gerner M, Hammerbeck C.D., Curtsinger JM. Activation-induced non-responsiveness (anergy) limits CD8 T cell responses to tumors. Semin Cancer Biol 2007; 17: 299-308.
46. + regulatory T cells. Cancer Res 2008; 68: 292-300.
47. Rigamonti N, Capuano G, Ricupito A., Jachetti E, Grioni M, Generoso L., et al. Modulators of arginine metabolism do not impact on peripheral T-cell tolerance and disease progression in a model of spontaneous prostate cancer. Clin Cancer Res 2011; 17: 1012-23.
48. Watkins SK, Zhu Z, Riboldi E., Shafer-Weaver KA, Stagliano KE, Sklavos M.M., et al. FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J Clin Invest 2011; 121: 1361-72.
49. Eyles J, Puaux AL, Wang X, Toh B., Prakash C, Hong M, et al Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Invest 2010; 120: 2030-9.
50. Shanmugam MK, Manu KA, Ong T.H., Ramachandran L., Surana R, Bist P, et al Inhibition of CXCR4/CXCL12 signaling axis by ursolic acid leads to suppression of metastasis in transgenic adenocarcinoma of mouse prostate model. Int J Cancer 2011; 129: 1552-63.